Ignite Creation Date:
2024-05-06 @ 3:56 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04810390
Status:
COMPLETED
Last Update Posted:
2023-03-16
First Post:
2021-03-01
Brief Title:
Study to Assess the Safety Tolerability and Efficacy of Bilastine Ophthalmic Solution 06 in Children
Sponsor:
Faes Farma SA
Organization:
Faes Farma SA
Study Overview
Official Title:
Multi-centre Randomised Double Blind Placebo-controlled Parallel Phase III Study to Assess the Safety Tolerability and Efficacy of Bilastine Ophthalmic Solution 06 in Children
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-centre randomised double blind placebo-controlled parallel-group phase III study to assess the safety tolerability and efficacy of Bilastine ophthalmic solution 06 in children with a documented history of seasonal allergic conjunctivitis SAC or perennial allergic conjunctivitis PAC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None